Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scotland R&D plant

This article was originally published in The Tan Sheet

Executive Summary

Mentholatum announces plans to create a state-of-the-art research and development center in East Kilbride, Scotland. The firm has already invested $20 million, which will increase production capacity at the plant owned by Mentholatum's Japan-based parent company, Rohto Pharmaceutical. Mentholatum says it "aims to cement its position as a market leader in the eye, lip and personal care categories and grow its presence in the skincare market on the back of its acquisition of the high-profile Oxy brand." Mentholatum acquired the brand from GlaxoSmithKline in December 2004 (1"The Tan Sheet" Dec. 20, 2004, p. 8)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel